NCT02196688View on ClinicalTrials.gov

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

November 30, 2015

Conditions
Colorectal Cancer
Interventions
DRUG

fruquintinib

fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

DRUG

placebo

Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

Trial Locations (5)

100071

Hutchison Medi Pharma Investigational Site, Beijing

150081

Hutchison Medi Pharma, Harbin

200032

Hutchison Medi Pharma Investigational Site, Shanghai

310016

Hutchison Medi Pharma Investigational Site, Hangzhou

510060

Hutchison Medi Pharma Investigational Site, Guangzhou

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Hutchison Medipharma Limited

INDUSTRY

NCT02196688 - Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter